Literature DB >> 33988335

The Full Spectrum of COVID-19 Development and Recovery Among Kidney Transplant Recipients.

Marina P Cristelli1, Laila A Viana1, Marcus T C Dantas1, Suelen B S Martins1, Ruan Fernandes1, Monica R Nakamura1, Daniel W C L Santos1, Julia B Taddeo1, Vega F Azevedo1, Renato D Foresto1, Helio Tedesco-Silva1, Jose Medina-Pestana1.   

Abstract

BACKGROUND: Coronavirus disease 2019 (COVID-19) fatality rate is high among kidney transplant recipients. Among survivors, kidney outcomes, seroconversion, and persistence of viral shedding are unexplored.
METHODS: Single-center prospective cohort study including data from kidney transplant recipients with confirmed COVID-19 between March 20, 2020 and July 31, 2020. Outcomes were adjudicated until August 31, 2020 or the date of death.
RESULTS: There were 491 patients with COVID-19 among the 11 875 recipients in follow-up. The majority were middle aged with ≥1 comorbidities. Thirty-one percent were treated at home, and 69% required hospitalization. Among the hospitalized, 61% needed intensive care, 75% presented allograft dysfunction, and 46% needed dialysis. The overall 28-day fatality rate was 22% and among hospitalized patients it was 41%. Age (odds ratio, 3.08; 95% confidence interval, 1.86-5.09), diabetes mellitus (odds ratio, 1.69; 95% confidence interval, 1.06-2.72), and cardiac disease (odds ratio, 2.00; 95% confidence interval, 1.09-3.68) were independent factors for death. Among the 351 survivors, 19% sustained renal graft dysfunction, and there were 13 (4%) graft losses. Biopsy (n = 20) findings were diverse but decisive to guide treatment and estimate prognosis. Seroconversion was observed in 79% of the survivors and was associated with disease severity. Persistence of viral shedding was observed in 21% of the patients without detectable clinical implications.
CONCLUSIONS: This prospective cohort analysis confirms the high 28-day fatality rate of COVID-19, associated primarily with age and comorbidities. The high incidence of allograft dysfunction was associated with a wide range of specific histologic lesions and high rates of sequelae and graft loss. Seroconversion was high and the persistence of viral shedding deserves further studies.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33988335     DOI: 10.1097/TP.0000000000003751

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

1.  Clinical characteristics, outcomes, and management of COVID-19 in kidney transplant recipients across Asia: an ASTREGO report.

Authors:  Terence Kee; Jong Cheol Jeong; Harun Ur-Rashid; Nura Afza Salma Begum; Mel-Hatra Arakama; Romina Danguilan; Lkhaahuu Od-Erdene; Rosnawati Yahya; Yaerim Kim; Hersharan Kaur Sran; Becky Ma; Maggie Ma; Devinder Singh Rana; Curie Ahn; Ghazali Ahmad
Journal:  Korean J Transplant       Date:  2021-12-31

2.  Efficacy of Convalescent Plasma to Treat Mild to Moderate COVID-19 in Kidney Transplant Patients: A Propensity Score Matching Analysis.

Authors:  Marina Pontello Cristelli; Dante Mário Langhi Junior; Laila Almeida Viana; Luis Gustavo Modelli de Andrade; Suelen Bianca Stopa Martins; Yasmim Cardoso Dreige; José Orlando Bordim; Helio Tedesco-Silva; José Medina-Pestana
Journal:  Transplantation       Date:  2022-01-01       Impact factor: 5.385

3.  One Year Into the Pandemic: Evolving COVID-19 Outcomes in Lung Transplant Recipients, a Single-center Experience.

Authors:  Kemarut Laothamatas; Jamie Hum; Luke Benvenuto; Lori Shah; Harpreet Singh Grewal; Marcus Pereira; Jenna Scheffert; Maggie Carroll; Margaret Nolan; Genevieve Reilly; Philippe Lemaitre; Bryan P Stanifer; Joshua R Sonett; Frank D'Ovidio; Hilary Robbins; Selim M Arcasoy
Journal:  Transplant Direct       Date:  2022-02-21

4.  Inactivated Whole-virus Vaccine Triggers Low Response Against SARS-CoV-2 Infection Among Renal Transplant Patients: Prospective Phase 4 Study Results.

Authors:  José Medina-Pestana; Dimas Tadeu Covas; Laila Almeida Viana; Yasmim Cardoso Dreige; Monica Rika Nakamura; Elizabeth França Lucena; Lucio R Requião-Moura; Carlos Magno Castelo Branco Fortaleza; Renato Demarchi Foresto; Helio Tedesco-Silva; Marina Pontello Cristelli
Journal:  Transplantation       Date:  2022-04-01       Impact factor: 4.939

5.  Impact of a National Multicentric Strategy to Support Kidney Transplant Patients During the COVID-19 Pandemic in Latin America: FUTAC Team Creation and Activities.

Authors:  Jacqueline Pefaur; Luis Toro; Eduardo Lorca; Ruben Torres
Journal:  Transplantation       Date:  2022-04-01       Impact factor: 4.939

6.  Benefits of Inactivated Vaccine and Viral Vector Vaccine Immunization on COVID-19 Infection in Kidney Transplant Recipients.

Authors:  Napun Sutharattanapong; Sansanee Thotsiri; Surasak Kantachuvesiri; Punlop Wiwattanathum
Journal:  Vaccines (Basel)       Date:  2022-04-08

Review 7.  COVID-19 and kidney disease: insights from epidemiology to inform clinical practice.

Authors:  Viyaasan Mahalingasivam; Guobin Su; Masao Iwagami; Mogamat Razeen Davids; James B Wetmore; Dorothea Nitsch
Journal:  Nat Rev Nephrol       Date:  2022-04-13       Impact factor: 42.439

8.  COVID-19 in Kidney Transplant Recipients With Diabetes Mellitus: A Propensity Score Matching Analysis.

Authors:  Érika B Rangel; Débora D de Lucena; Isabella Aguiar-Brito; Luís Gustavo Modelli de Andrade; Alexandre Veronese-Araújo; Marina P Cristelli; Hélio Tedesco-Silva; José O Medina-Pestana
Journal:  Transpl Int       Date:  2022-07-25       Impact factor: 3.842

9.  Immunogenicity After a Heterologous BNT262b2 Versus Homologous Booster in Kidney Transplant Recipients Receiving 2 Doses of CoronaVac Vaccine: A Prospective Cohort Study.

Authors:  José Medina-Pestana; Laila Almeida Viana; Monica Rika Nakamura; Elizabeth França Lucena; Celso Francisco Hernandes Granato; Yasmim Cardoso Dreige; Laysla Verhalen Pouzo Amorim; Charles Yea Zen Chow; Renato Demarchi Foresto; Lucio Roberto Requião-Moura; Helio Tedesco-Silva; Marina Pontello Cristelli
Journal:  Transplantation       Date:  2022-08-05       Impact factor: 5.385

10.  Association Between Maintenance Immunosuppressive Regimens and COVID-19 Mortality in Kidney Transplant Recipients.

Authors:  Alexandre O Gérard; Susana Barbosa; Dany Anglicheau; Lionel Couzi; Marc Hazzan; Olivier Thaunat; Gilles Blancho; Sophie Caillard; Antoine Sicard
Journal:  Transplantation       Date:  2022-07-27       Impact factor: 5.385

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.